APA (7th ed.) Citation

W, L., S, B., FL, W., JM, Y., JS, F., HM, H., . . . JL, K. (2022). Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: A single-arm, open-label, phase 2, non-inferiority trial. The Lancet. Child & adolescent health, 6(1), 38. https://doi.org/10.1016/S2352-4642(21)00278-9

Chicago Style (17th ed.) Citation

W, Landier, et al. "Immunogenicity and Safety of the Human Papillomavirus Vaccine in Young Survivors of Cancer in the USA: A Single-arm, Open-label, Phase 2, Non-inferiority Trial." The Lancet. Child & Adolescent Health 6, no. 1 (2022): 38. https://doi.org/10.1016/S2352-4642(21)00278-9.

MLA (9th ed.) Citation

W, Landier, et al. "Immunogenicity and Safety of the Human Papillomavirus Vaccine in Young Survivors of Cancer in the USA: A Single-arm, Open-label, Phase 2, Non-inferiority Trial." The Lancet. Child & Adolescent Health, vol. 6, no. 1, 2022, p. 38, https://doi.org/10.1016/S2352-4642(21)00278-9.